New drug duo takes on Hard-to-Treat waldenstrom macroglobulinemia

NCT ID NCT07548450

Not yet recruiting Disease control Sponsor: University of Utah Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase II trial is testing the safety and effectiveness of combining two drugs, mosunetuzumab and pirtobrutinib, in 25 adults with relapsed or refractory Waldenstrom Macroglobulinemia, a rare blood cancer. Participants must have had at least one prior treatment. The study aims to find the best dose and see how well the combination shrinks tumors.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: mosunetuzumab and pirtobrutinib
What this could lead to: If successful, this combination could offer a new treatment option for patients with Waldenstrom Macroglobulinemia whose cancer has returned or stopped responding to prior therapy.
What could go wrong: This is an early phase II trial with only 25 participants, so results may not apply to all patients. The combination may cause side effects or not work better than existing treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for WALDENSTROM MACROGLOBULINEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Waldenstrom macroglobulinemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

WALDENSTROM MACROGLOBULINEMIA

Contacts and locations

Locations

Huntsman Cancer Institute at University of Utah

Salt Lake City, Utah, 84112, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.